<DOC>
	<DOCNO>NCT02461849</DOCNO>
	<brief_summary>KIT receptor tyrosine kinase bind stem-cell factor ( SCF ) , activate series downstream effector pathway . KIT establish therapeutic target cancer activate mutation KIT , gastrointestinal stromal tumor ( GIST ) , significant benefit achieve various small molecule inhibitor KIT imatinib mesylate . Moreover , increase evidence implicate KIT mutation tractable therapeutic target melanoma . Additional information require characterize functional role low-frequency mutation KIT determine whether amplification wild type KIT real driver target therapeutically . Except GIST melanoma , solid cancer report KIT mutation even low frequency . A molecular profiling tumor patient refer phase I clinic M.D . Anderson Cancer Center show KIT mutation 7 patient total 431 patient ( 2 % ) . Hence , investigator plan study apply molecularly target agent , imatinib various type cancer harbor KIT mutation amplification .</brief_summary>
	<brief_title>Patients With Refractory , Metastatic Cancer Harboring KIT Mutation Amplification Investigate Clinical Efficacy Safety Imatinib Therapy</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>1. age ≥ 20 2. advanced , refractory cancer patient fail standard care ( SOC ) 3 . KIT aberration : define mutation exon 9 , 11 , 13 , 17 18 , nanostring CNV quantitative PCR ( great 3 copy ) subject specific sensitivity ( Zscore &lt; 1 ) imatinib Avatar scan whose disease progress follow standard therapy respond standard therapy standard therapy 4 . ECOG performance status 0~2 5. measurable evaluable lesion per RECIST 1.1 criterion 6. adequate marrow , hepatic , renal cardiac function Serum aspartate transaminase ( AST ) serum alanine transaminase ( ALT ) ≤ 2.5 x upper limit normal ( ULN ) , AST ALT ≤ 5 x ULN liver function abnormality due underlie malignancy Total serum bilirubin ≤ 1.5 x ULN Absolute neutrophil count ( ANC ) ≥ 1,500/uL Platelets ≥ 100,0000/uL Hemoglobin ≥ 9.0 g/dL 7. provision sign write informed consent 1. severe comorbid illness and/or active infection 2. pregnant lactate woman 3. history major surgery radiotherapy within 4 week 4. active CNS metastasis controllable radiotherapy corticosteroid ( however , CNS metastases ( except leptomeningeal seed ) allow control gamma knife surgery surgery radiotherapy steroid ) 5. know history hypersensitivity study drug</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>